Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-768

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-768 Category Tag

Product Details

Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Camidanlumab tesirine (Cami-T or ADCT-31) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin.
The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin’s lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Products Name (INN Index)

Pre-Made Camidanlumab Tesirine Biosimilar, Whole Mab Adc, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody Drug Conjugate

INN Name

camidanlumab tesirine

Target

IL2RA

Format

Whole mAb ADC

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1 – kappa

VD LC

IgG1 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Genmab?A/S (Copenhagen Denmark) / ADC Therapeutics (Epalinges Switzerland)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL2RA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide